Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable

a multivariate regression analysis of 163 untreated patients.

M. Cavo, P. Galieni, M. Grimaldi, E. Zuffa, M. A. Bonelli, M. Gobbi, S. Tura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The presenting clinical features of 163 previously untreated patients with multiple myeloma were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, haemoglobin level (Hb), tumour cell mass stage, lytic bone lesions, creatinine and age. When the individual contribution of each variable was assessed by multivariate regression analysis, platelet count was confirmed to be the dominant feature for prognosis, while clinical stage provided additional information. The introduction of platelet count could then be used to improve the discriminating power of Durie & Salmon staging, by allowing separation of the high-risk group (stages II and III) into a smaller subgroup (22%) of thrombocytopenic patients (less than 150 x 10(9) platelets/l) whose risk of death was actually very high (median survival: 9 months) and a larger subgroup (46%) of patients with normal platelet count and intermediate or standard risk (median survival: 48 months).

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalEuropean Journal of Haematology, Supplement
Volume51
Publication statusPublished - 1989

Fingerprint

Salmon
Multiple Myeloma
Platelet Count
Multivariate Analysis
Regression Analysis
Survival
Creatinine
Hemoglobins
Blood Platelets
Bone and Bones
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable : a multivariate regression analysis of 163 untreated patients. / Cavo, M.; Galieni, P.; Grimaldi, M.; Zuffa, E.; Bonelli, M. A.; Gobbi, M.; Tura, S.

In: European Journal of Haematology, Supplement, Vol. 51, 1989, p. 99-104.

Research output: Contribution to journalArticle

@article{02d051f090304944985d9fd172c7bb42,
title = "Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: a multivariate regression analysis of 163 untreated patients.",
abstract = "The presenting clinical features of 163 previously untreated patients with multiple myeloma were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, haemoglobin level (Hb), tumour cell mass stage, lytic bone lesions, creatinine and age. When the individual contribution of each variable was assessed by multivariate regression analysis, platelet count was confirmed to be the dominant feature for prognosis, while clinical stage provided additional information. The introduction of platelet count could then be used to improve the discriminating power of Durie & Salmon staging, by allowing separation of the high-risk group (stages II and III) into a smaller subgroup (22{\%}) of thrombocytopenic patients (less than 150 x 10(9) platelets/l) whose risk of death was actually very high (median survival: 9 months) and a larger subgroup (46{\%}) of patients with normal platelet count and intermediate or standard risk (median survival: 48 months).",
author = "M. Cavo and P. Galieni and M. Grimaldi and E. Zuffa and Bonelli, {M. A.} and M. Gobbi and S. Tura",
year = "1989",
language = "English",
volume = "51",
pages = "99--104",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable

T2 - a multivariate regression analysis of 163 untreated patients.

AU - Cavo, M.

AU - Galieni, P.

AU - Grimaldi, M.

AU - Zuffa, E.

AU - Bonelli, M. A.

AU - Gobbi, M.

AU - Tura, S.

PY - 1989

Y1 - 1989

N2 - The presenting clinical features of 163 previously untreated patients with multiple myeloma were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, haemoglobin level (Hb), tumour cell mass stage, lytic bone lesions, creatinine and age. When the individual contribution of each variable was assessed by multivariate regression analysis, platelet count was confirmed to be the dominant feature for prognosis, while clinical stage provided additional information. The introduction of platelet count could then be used to improve the discriminating power of Durie & Salmon staging, by allowing separation of the high-risk group (stages II and III) into a smaller subgroup (22%) of thrombocytopenic patients (less than 150 x 10(9) platelets/l) whose risk of death was actually very high (median survival: 9 months) and a larger subgroup (46%) of patients with normal platelet count and intermediate or standard risk (median survival: 48 months).

AB - The presenting clinical features of 163 previously untreated patients with multiple myeloma were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, haemoglobin level (Hb), tumour cell mass stage, lytic bone lesions, creatinine and age. When the individual contribution of each variable was assessed by multivariate regression analysis, platelet count was confirmed to be the dominant feature for prognosis, while clinical stage provided additional information. The introduction of platelet count could then be used to improve the discriminating power of Durie & Salmon staging, by allowing separation of the high-risk group (stages II and III) into a smaller subgroup (22%) of thrombocytopenic patients (less than 150 x 10(9) platelets/l) whose risk of death was actually very high (median survival: 9 months) and a larger subgroup (46%) of patients with normal platelet count and intermediate or standard risk (median survival: 48 months).

UR - http://www.scopus.com/inward/record.url?scp=0024892168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024892168&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 99

EP - 104

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

ER -